HIGHLIGHTS
- who: Ziling Xiang from the development of orphan drugs in China have published the paper: Current status and trend of clinical development of orphan drugs in China, in the Journal: (JOURNAL) of December/31,/2021
- what: Many pharmaceutical companies tend to develop generic drugs, instead of original drugs, mainly due to the following reasons.
SUMMARY
The approved list of orphan_drugs is limited due to many hurdles in the processes of drug development. A study showed that a total of 133 orphan_drugs covering 179 rare diseases, were approved in the EU in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.